logo

For the Inventor, By the Inventor

Austin, TX, United States of America

Karl A Folkers

This inventor holds 23 USPTO granted patents, primarily in Hormonal Peptides. Top assignees: The University of Texas System, The Administrators of the Tulane Educational Fund, Biomedical and Clinical Research. Active years: 1976-2002.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Karl A Folkers. Retrieved from https://idiyas.com/inventor/karl-a-folkers

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 23

% Patents Active = 100.0

Average Co-Inventor Count = 2.7

ph-index = 8

Forward Citations = 293(Granted Patents)


Company Filing History:

goldMedal14 out of 5,638 
 
The University of Texas System
 patents
silverMedal4 out of 249 
 
The Administrators of the Tulane Educational Fund
 patents
bronzeMedal1 out of 1 
 
Biomedical and Clinical Research
 patent
4. 1 out of 1 
 
Karl Folkers Foundation for Biomedical and Clinical Research
 patent
5. 7 out of 834,513 
Other
 patents
where one patent can have more than one assignee

Years Active: 1976-2002

Loading Chart...
Areas of Expertise:
Coenzyme Q10
LHRH Antagonists
Hormonal Peptides
Cardiomyopathy
Periodontal Disease
Thymones
Peptide Antagonists
Intravenous Formulations
Synthetic Decapeptides
Antiovulatory Activity
Biologically Active Compounds
Effective Antagonists
23 patents (USPTO):Explore Patents
1. 6461593 - Therapy with coenzyme Q10 to reduce subgingival microorganisms in patients with periodontal disease (2002-10-08),
2. 5763404 - Methods for using LHRH antagonists with low histamine release (1998-06-09),
3. 5656727 - Antagonists of LHRH (1997-08-12),
4. 5480969 - Antagonists of LHRH (1996-01-02),
5. 5470947 - CHRH antagonists with low histamine release (1995-11-28),
6. 5316765 - Use of coenzyme Q.sub.10 in combination with HMG-CoA reductase inhibitor (1994-05-31),
7. 5082650 - Amelioration of reductions of coenzyme Q.sub.10 in cardiomyopathy (1992-01-21),
8. 5011858 - Therapy with coenzyme Q.sub.10 of patients having AIDS or other (1991-04-30),
9. 4935491 - Effective antagonists of the luteinizing hormone releasing hormone which (1990-06-19),
10. 4885167 - Restoration of impaired cardiac function of patients with diverse (1989-12-05),
11. 4824669 - Formulations of coenzyme Q.sub.10 for intravenous use (1989-04-25),
12. 4721775 - Effective peptides related to the luteinizing hormone releasing hormone (1988-01-26),
13. 4656247 - Effective hormonal peptides: D-3-QA1 6-LHRH (1987-04-07),
14. 4642332 - Effective hormonal peptides: D-3-Pal.sup.6 -LHRH (1987-02-10),
15. 4550109 - Lipoidal biopterin compounds (1985-10-29),

Title: The Innovative Contributions of Karl A. Folkers in Medical Research

Introduction

Karl A. Folkers, based in Austin, TX, is a notable figure in the field of medical research and innovation. With an impressive portfolio of 23 patents, his contributions have significantly advanced the understanding and treatment of various medical conditions, particularly in the realm of peptide therapies.

Latest Patents

Folkers' recent patents showcase his pioneering work. One of them focuses on a therapy utilizing coenzyme Q10 to reduce subgingival microorganisms in patients suffering from periodontal disease. Additionally, he developed methods for using LHRH antagonists with minimal histamine release. His innovative decapeptide, known as Antide, serves as an antagonist to luteinizing hormone releasing hormone (LHRH). This peptide exhibits high antiovulatory activity and shows promise for further development in clinical settings. Notably, modifications to the peptide structure have led to the synthesis of numerous related compounds, some of which demonstrated enhanced antiovulatory potency compared to Antide itself.

Career Highlights

Karl A. Folkers has made remarkable strides throughout his career. He has held significant positions within the University of Texas System, contributing to groundbreaking research and development. His extensive work in peptide synthesis and hormone antagonism elucidates his expertise in medical innovations and drug development.

Collaborations

Folkers has collaborated with esteemed researchers such as Cyril Y. Bowers and Anders Ljungqvist. These partnerships have fostered an environment of innovation, allowing for the sharing of knowledge and expertise that has accelerated advancements in peptide therapies and their potential applications in medicine.

Conclusion

Karl A. Folkers continues to play a crucial role in the development of innovative medical solutions through his extensive patent portfolio and collaborative research efforts. His dedication to exploring new therapeutic avenues ensures that his contributions will have a lasting impact on the medical community.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…